VEGFA and neoplasm: Different mechanisms of resistance to antiangiogenics include (i) alternative angiogenic pathways activation (vascular endothelial growth factor‐independent manner), (ii) recruitment of bone marrow‐derived cells (M2 tumor‐associated macrophages, myeloid‐derived suppressor cells, regulatory T cells) and cancer‐associated fibroblasts promoting tumor growth and epithelial‐to‐mesenchymal transition, and (iii) participation of malignant cells in neovascularization (vasculogenic mimicry, vasculogenesis, or splitting angiogenesis).38